This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bruckner, H. W. Articles by Mitchell, M. S. Search for Related Content PubMed PubMed Citation Articles by Bruckner, H. W. Articles by Mitchell, M. S.

Effect of Imidazole-4-carboxamide, 5-(3,3-Dimethyl-1-triazeno) on Immunity in Patients with Malignant Melanoma¹

Departments of Internal Medicine and Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06510

Imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazeno), NSC 45388 (DTIC), was administered for 5 consecutive days as a rapid 150-mg/sq m or 250-mg/sq m infusion to 13 patients with melanoma. DTIC did not interfere with induction of a cellular immune (delayed hypersensitivity) response to dinitrochlorobenzene in 7 of 12 patients tested or with established delayed hypersensitivity reactions in 8 of 8 patients. The 5 nonresponders to dinitrochlorobenzene were unable to manifest a cellular immune response to skin test antigens even before treatment with DTIC. DTIC did not suppress the primary humoral response to Vi antigen in 7 of 12 patients. The secondary response to tetanus toxoid was normal in 5 of 7 patients. These results indicate that DTIC at these dosage schedules was only moderately immunosuppressive and inhibited humoral immune responses slightly more than the cellular responses tested.

¹ Supported by USPHS Research Grants CA 08341 and CA 13105 and American Cancer Society Grant IC-72.

² Recipient of USPHS Special Fellowship IF-3, Grant CA 51650-01, and American Cancer Society Grant PF 826.

³ Scholar of the Leukemia Society of America. To whom reprint requests should be addressed at Department of Medicine, Yale University, School of Medicine, 333 Cedar St., New Haven, Conn.

Received 6/ 1/73. Accepted 10/11/73.

This article has been cited by other articles:

				C. Garbe, P. Radny, R. Linse, R. Dummer, R. Gutzmer, J. Ulrich, R. Stadler, M. Weichenthal, TK. Eigentler, U. Ellwanger, et al. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis Ann. Onc., June 1, 2008; 19(6): 1195 - 1201. [Abstract] [Full Text] [PDF]

				M. S. Mitchell Chemotherapy for Melanoma: The Resultant of Conflicting Vectors J. Clin. Oncol., June 1, 2004; 22(11): 2043 - 2045. [Full Text] [PDF]